ArticleStem cell reports2021
Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes.
Article in Stem cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 80 citations in OpenAlex.
- The making of cells and organs in xenogeneic animal bioreactor.Signal transduction and targeted therapy · 2026Review
- In silico optimization of regenerative cell therapy in the infarcted human ventricles to mitigate arrhythmic burden.Stem cell reports · 2026Article
- Spatiotemporal transcriptomics of human cardiovascular progenitors in pig hearts identifies Midkine as a positive regulator of neovascularization.Nature cardiovascular research · 2026Article
- Circumferential strain recovery after human cardiomyocyte transplantation in minipigs using a novel frequency-based method for myocardial tagging quantification.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2026Article
- Electrical coupling between transplanted cardiomyocytes and host myocardium to prevent arrhythmia.Disease models & mechanisms · 2026Review
- Accelerated Intrinsic Beating Rate in Heterogeneously Coupled Human Pluripotent Stem Cell-Derived Cardiomyocytes Can Underlie Focal Ventricular Tachycardia in Regenerative Therapy.Journal of precision medicine (Amsterdam, Netherlands) · 2026Article
- Prioritizing Discovery and Advancements in Arrhythmia Therapies: NIH/NHLBI Workshop.JACC. Clinical electrophysiology · 2026Review
- Mechanisms and Therapeutic Potential of Human Cardiomyocyte Proliferation.Journal of cardiovascular development and disease · 2026Review
- Phase resetting in human stem cell derived cardiomyocytes explains complex cardiac arrhythmias.PLoS computational biology · 2026Article
- Current Trends in Duchenne Muscular Dystrophy Research and Therapy: 3D Cardiac Modelling.Journal of cachexia, sarcopenia and muscle · 2026Review
- Progress and challenges in transplantation of human pluripotent stem cell derived cardiomyocytes for cardiac therapy.npj biomedical innovations · 2026Review
- Heart Regeneration for Clinical Application.Internal medicine (Tokyo, Japan) · 2026Review
- Recent Advances of Pluripotent Stem Cell-Derived Cardiomyocytes for Regenerative Medicine.Metabolites · 2025Review
- Pluripotent stem cell-based approaches for heart repair and the potential of genetic modifications.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Computational Simulations Show Proof-of-Concept for Optogenetic Suppression of Ectopic Activity in Cardiac Stem Cell Therapy.Cardiovascular engineering and technology · 2025Article
- Exploring hiPSC-CM replacement therapy in ischemic hearts.Basic research in cardiology · 2025Review
- Selegiline protects against isoproterenol-induced myocardial ischemia injury: a potential mechanistic role of the PI3K/AKT/mTOR signaling pathway.Research in pharmaceutical sciences · 2025Article
- Population-based computational simulations elucidate mechanisms of focal arrhythmia following stem cell injection.Journal of molecular and cellular cardiology · 2025Article
- Human Cardiac Microtissues Display Improved Engraftment and Survival in a Porcine Model of Myocardial Infarction.Journal of cardiovascular translational research · 2025Article
- Transcriptome-wide RNA 5-methylcytosine profiles of human iPSCs and iPSC-derived cardiomyocytes.Scientific data · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 3 institutions in 1 country.
Funding
Abstract
Heart failure remains a significant cause of morbidity and mortality following myocardial infarction. Cardiac remuscularization with transplantation of human pluripotent stem cell-derived cardiomyocytes is a promising preclinical therapy to restore function. Recent large animal data, however, have revealed a significant risk of engraftment arrhythmia (EA). Although transient, the risk posed by EA presents a barrier to clinical translation. We hypothesized that clinically approved antiarrhythmic drugs can prevent EA-related mortality as well as suppress tachycardia and arrhythmia burden. This study uses a porcine model to provide proof-of-concept evidence that a combination of amiodarone and ivabradine can effectively suppress EA. None of the nine treated subjects experienced the primary endpoint of cardiac death, unstable EA, or heart failure compared with five out of eight (62.5%) in the control cohort (hazard ratio = 0.00; 95% confidence interval: 0-0.297; p = 0.002). Pharmacologic treatment of EA may be a viable strategy to improve safety and allow further clinical development of cardiac remuscularization therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.